ACCC | ACCC Submits Comments to FDA on Draft Guidance to Increase Diversity in Clinical Trials
ACCC Submits Comments to FDA on Draft Guidance to Increase Diversity in Clinical Trials
The ACCC Community Oncology Research Institute (ACORI) Task Force submitted comments to the Food and Drug Administration (FDA) in response to the agency's draft guidance on Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials.
LOS 2026 Cancer Congress - National Oncology Updates
In Person Conference & ConventionAugust 14, 2026 at 11:00 AM CDT859 Convention Center Blvd, New Orleans, LA, USANew Orleans Marriott Warehouse Art District, New Orleans
In Person Conference & ConventionAugust 22, 2026 at 6:30 AM CDT300 East 9th Street, Coralville, IA, USAHyatt Regency Coralville Hotel & Conference Center, Coralville
